Global Information
회사소개 | 문의 | 비교리스트

모발상세포 백혈병 : 파이프라인 리뷰

Hairy Cell Leukemia - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 253659
페이지 정보 영문 125 Pages
가격
US $ 2,000 ₩ 2,410,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,820,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,230,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


모발상세포 백혈병 : 파이프라인 리뷰 Hairy Cell Leukemia - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 125 Pages

모발상세포 백혈병은 완만한 경과를 나타내는 희귀 혈액암으로, 골수가 B세포(림프구)를 과잉으로 만들게 됩니다. 피로, 멍이 쉽게 발생, 감염증 재발, 허약, 체중 감소 등의 증상을 볼 수 있습니다. 위험인자는 방사선·화학물질에 대한 노출 등이 포함됩니다. 치료는 외과수술, 화학요법, 방사선요법 등이 실시됩니다.

모발상세포 백혈병(Hairy Cell Leukemia)에 대한 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 프로파일, 파이프라인 제품 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

모발상세포 백혈병 : 개요

모발상세포 백혈병 - 치료제 개발

  • 파이프라인 제품 개요
  • 기업에서 개발된 파이프라인
  • 기업에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여 기업

  • AbbVie Inc
  • ARA Healthcare Pvt Ltd
  • Astellas Pharma Inc.
  • Cellectis SA
  • F. Hoffmann-La Roche Ltd
  • Incyte Corp
  • Juno Therapeutics Inc
  • MedImmune LLC
  • Novartis AG

약제 프로파일

휴지 상태인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 17.06.05

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Hairy Cell Leukemia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Hairy Cell Leukemia - Pipeline by AbbVie Inc, H1 2020
  • Hairy Cell Leukemia - Pipeline by AstraZeneca Plc, H1 2020
  • Hairy Cell Leukemia - Pipeline by Cellular Biomedicine Group Inc, H1 2020
  • Hairy Cell Leukemia - Pipeline by Elsalys Biotech SA, H1 2020
  • Hairy Cell Leukemia - Pipeline by Eureka Therapeutics Inc, H1 2020
  • Hairy Cell Leukemia - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
  • Hairy Cell Leukemia - Pipeline by Incyte Corp, H1 2020
  • Hairy Cell Leukemia - Pipeline by Novartis AG, H1 2020
  • Hairy Cell Leukemia - Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, H1 2020
  • Hairy Cell Leukemia - Pipeline by Xynomic Pharmaceuticals Holdings Inc, H1 2020
  • Hairy Cell Leukemia - Dormant Projects, H1 2020
  • Hairy Cell Leukemia - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Hairy Cell Leukemia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hairy Cell Leukemia - Pipeline Review, H1 2020, provides an overview of the Hairy Cell Leukemia (Oncology) pipeline landscape.

Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hairy Cell Leukemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hairy Cell Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hairy Cell Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hairy Cell Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 6, 3 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0 and Preclinical stages comprises 2, 1, 1 and 1 molecules, respectively.

Hairy Cell Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hairy Cell Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hairy Cell Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hairy Cell Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hairy Cell Leukemia (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hairy Cell Leukemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hairy Cell Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Hairy Cell Leukemia - Overview
  • Hairy Cell Leukemia - Therapeutics Development
  • Hairy Cell Leukemia - Therapeutics Assessment
  • Hairy Cell Leukemia - Companies Involved in Therapeutics Development
  • Hairy Cell Leukemia - Drug Profiles
  • Hairy Cell Leukemia - Dormant Projects
  • Hairy Cell Leukemia - Discontinued Products
  • Hairy Cell Leukemia - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q